caa a22 4500 47706163X CHVBK 20180405111402.0 cr unu---uuuuu 170330e19960301xx s 000 0 eng 10.1007/BF01061913 doi (NATIONALLICENCE)springer-10.1007/BF01061913 Newer antithrombotic agents: Potential for clinical use in venous and arterial thrombosis [Elektronische Daten] [Barbara Alving, Andrew Carter] Advances in the understanding of the pathophysiology of thrombosis and in the ability to produce recombinant or chimeric proteins that are active against thrombin or specific platelet receptors have resulted in the development of several new agents. Some of these antiplatelet agents and direct thrombin inhibitors are available now; others are likely to be approved by the U.S. Food and Drug Administration for release in the near future. This brief review discusses selected examples of the multiple agents that are currently in use or are likely to be used in specific clinical settings. Ticlopidine, one of the newer antiplatelet agents, is efficacious in reducing the risk of stroke in patients with known cerebrovascular or ischemic heart disease. The chimeric monoclonal antibody c7E3 Fab is a potent platelet GP IIb/IIIa receptor antagonist that has been extensively investigated. Integrelin is a cyclic heptapeptide directed against GP IIb/IIIa. The most potent naturally occurring thrombin inhibitor is hirudin, a 7 kD protein produced by the European medicinal leech,Hirudo medicinalis. Unlike heparin, hirudin can inhibit both free and clot-bound thrombin. Hirulog is a synthetic analog of hirudin. Defining the appropriate use of these antithrombotic agents and developing methods for rapid, accurate laboratory monitoring remain major challenges, but the future is a pomising one for these newer antithrombotic agents. Kluwer Academic Publishers, 1996 thrombosis nationallicence hirudin nationallicence antiplatelet agents nationallicence Alving Barbara Department of Hematology and Vascular Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC aut Carter Andrew Department of Hematology and Vascular Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC aut Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 2/4(1996-03-01), 285-288 0929-5305 2:4<285 1996 2 11239 https://doi.org/10.1007/BF01061913 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01061913 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Alving Barbara Department of Hematology and Vascular Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC aut NATIONALLICENCE 700 1- Carter Andrew Department of Hematology and Vascular Biology, Walter Reed Army Institute of Research, 20307-5100, Washington, DC aut NATIONALLICENCE 773 0- Journal of Thrombosis and Thrombolysis Kluwer Academic Publishers 2/4(1996-03-01), 285-288 0929-5305 2:4<285 1996 2 11239 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer